Browse News
Filter News
Found 82 articles
-
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
11/14/2023
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today provides a corporate update for the third quarter ending September 30, 2023.
-
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
11/7/2023
Qualigen Therapeutics, Inc. announces today that the first patient in the Phase 1a clinical trial has been dosed with QN-302, a potential first-in-class, investigational G-Quadruplex (G4)-selective transcription inhibitor designed for the treatment of advanced or metastatic solid tumors.
-
Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors
8/17/2023
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced today it is partnering with Translational Drug Development (TD2) as the contract research organization (CRO) to conduct the Phase 1 clinical development of lead drug candidate QN-302.
-
C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring
1/31/2023
C-mo Medical Solutions is a pioneering Digital Health start-up that is unlocking the power of cough monitoring. The company has now secured additional funding from Novalis Biotech to advance its mission of revolutionising cough assessment and disease management.
-
Actinic Keratosis Treatment Market Size, Share, Growth, Trends, Forecast 2021 to 2030
11/10/2022
The global actinic keratosis treatment market size is expected to be worth around US$ 10.12 billion by 2030, according to a new report by Vision Research Reports.
-
Healthcare Financial Analytics Market Segmentation and Analysis Report, 2031
9/6/2022
The healthcare financial analytics market is prognosticated to observe steady growth during the forecast period of 2021-2031.
-
Infertility Testing and Treatment Market Insights and Emerging Trends by 2031
9/2/2022
Wilmington, Delaware, United States, Transparency Market Research Inc. – Infertility is defined as the inability to conceive naturally after one year of unprotected copulation.
-
Cell Therapy Technologies Market: Increase in Mergers and Acquisitions Among the Key Players to Drive the Global Market
9/2/2022
Wilmington, Delaware, United States, Transparency Market Research Inc. – Cell therapy is also popularly known as cellular therapy or cytotherapy.
-
Biosimilar Contract Manufacturing Market Size, Share, Growth, Report 2022-2030
8/29/2022
According to Vision Research Reports, the global biosimilar contract manufacturing market was valued at USD 5.5 billion in 2021 and it is predicted to surpass around USD 25.9 billion by 2030 with a CAGR of 18.79% from 2022 to 2030.
-
SELLAS Life Sciences’ Highly Selective CDK9 Inhibitor, GFH009, Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Model of Neuroendocrine Prostate Cancer Cell Line
8/24/2022
SELLAS Life Sciences Group, Inc. today announced results from a new preclinical in vitro study for its highly selective CDK9 inhibitor, GFH009, in neuroendocrine prostate cancer (NEPC).
-
Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board
8/18/2022
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), today announces it has formed a Scientific Advisory Board (SAB) in support of the development of its lead therapeutic candidate QN-302 for the potential treatment of pancreatic cancer and other G4-prevalent solid tumors.
-
SELLAS Life Sciences’ GFH009 Demonstrates Cancer Cell Growth Inhibition in Preclinical In Vitro Studies in Solid Cancer and Acute Myeloid Leukemia Cell Lines
8/9/2022
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced results from preclinical in vitro studies for its highly selective CDK9 inhibitor, GFH009, in solid cancer and acute myeloid leukemia (AML) cell lines.
-
Voltron Therapeutics, Inc., a Lucius Partners Company, Announces Initiation of Key Preclinical Study of VTX-067 in Immuno-Oncology
6/23/2022
Lucius Partners, LLC today reported that its portfolio company, Voltron Therapeutics, Inc., had announced the initiation of a preclinical study of its novel vaccine candidate VTX-067 in an immune-oncology model.
-
NRG Therapeutics Announces £2.68M Innovate UK Award to Develop New Medicines to Treat Parkinson’s and Motor Neuron Disease
5/31/2022
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.
-
Tracheostomy Products Market Size, Share, Growth, Trends | Report 2022-2030
5/23/2022
The volume of surgical operations has increased with the rising incidence of chronic respiratory illnesses, such as Cardiovascular Diseases (CVDs), diabetes, respiratory diseases, cancer, or other respiratory injuries.
-
Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results
5/13/2022
Qualigen Therapeutics, Inc. announces its financial results for the first quarter ended March 31, 2022, and provides an update on its diagnostics business, therapeutics pipeline, and other corporate developments.
-
Biopharmaceutical Third Party Logistics Market Size US$ 150.2 BN 2030
4/26/2022
The global biopharmaceutical third party logistics market size is expected to surpass around US$ 150.2 billion by 2030 and expanding growth at a CAGR of 6.6% from 2021 to 2030.
-
Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302
3/30/2022
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has appointed the renowned contract research organization (CRO) Translational Drug Development (TD2) to lead the preclinical development of lead drug candidate QN-302.
-
TD2 Partners with Medidata to Enhance its Clinical Operations and Accelerate Clinical Trials
10/14/2021
Medidata, a Dassault Systèmes company, today announced that Translational Drug Development (TD2), a precision oncology contract research organization (CRO), has signed an agreement to adopt Medidata’s Rave CTMS (Clinical Trial Management System) and eTMF (electronic Trial Master File) solutions.
-
Certis Oncology Offers Translational Science Services to Pharmaceutical Industry, Welcomes New Business Development Leader
1/5/2021
Certis Oncology Solutions, a precision oncology and translational sciences company, announced it will make available its personalized approach to drug efficacy testing to the commercial pharmaceutical industry.